Literature DB >> 10202981

Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine.

M Sakurai1, I Kanazawa.   

Abstract

Patients with multiple sclerosis (MS) often show positive symptoms of painful tonic seizure and dysesthesia as well as negative symptoms of paralysis and hypesthesia. Positive manifestation is paroxysmal and/or persistent. These are considered to be mediated by ectopic impulses generated at the site of demyelination, whereas negative symptoms are caused by conduction block. Conduction block at a demyelinated segment should reduce positive symptoms, but worsen negative ones. As reported previously, lidocaine, an Na channel blocker unmasks silent negative symptoms presumably by further reducing the action current in demyelinated portions and blocking conduction. Furthermore, because it blocks Na channels in a voltage- and frequency dependent manner, fibers that mediate positive symptoms are preferentially blocked. We administered lidocaine to 30 MS patients with positive symptoms. Lidocaine (mean plasma level, 2.4 pg/ml) almost completely abolished the paroxysmal manifestation of painful tonic seizures, neuralgic attacks, paroxysmal itching, and Lhermitte's sign. It also markedly alleviated persistent symptoms, but less so than paroxysmal symptoms. Similar effects were obtained with orally-administered mexiletine (300-400 mg/day), a derivative of lidocaine, but to a lesser extent. Na channel blockers have a dual effect on symptoms in MS, depending on whether symptoms are positive or negative. The mechanism that produces positive symptoms and the effects of the drugs on these symptoms are discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10202981     DOI: 10.1016/s0022-510x(98)00322-0

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  22 in total

1.  Imbalance of ionic conductances contributes to diverse symptoms of demyelination.

Authors:  Jay S Coggan; Steven A Prescott; Thomas M Bartol; Terrence J Sejnowski
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

2.  Topiramate therapy for symptomatic trigeminal neuralgia.

Authors:  A Siniscalchi; L Gallelli; D Scornaienghi; F Mancuso; G De Sarro
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 3.  Sodium channel blockers for the treatment of neuropathic pain.

Authors:  Anindya Bhattacharya; Alan D Wickenden; Sandra R Chaplan
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

4.  Lesion correlates of secondary paroxysmal dyskinesia in multiple sclerosis.

Authors:  Kilian Fröhlich; Klemens Winder; Ralf A Linker; Konstantin Huhn; Tobias Engelhorn; Arnd Dörfler; De-Hyung Lee; Stefan Schwab; Frank Seifert
Journal:  J Neurol       Date:  2018-07-31       Impact factor: 4.849

5.  Cooperativity between remote sites of ectopic spiking allows afterdischarge to be initiated and maintained at different locations.

Authors:  Jay S Coggan; Terrence J Sejnowski; Steven A Prescott
Journal:  J Comput Neurosci       Date:  2015-05-01       Impact factor: 1.621

Review 6.  Intravenous lidocaine and mexiletine in the management of trigeminal autonomic cephalalgias.

Authors:  Michael J Marmura
Journal:  Curr Pain Headache Rep       Date:  2010-04

Review 7.  Pharmacological management of pain in patients with multiple sclerosis.

Authors:  Claudio Solaro; Michele Messmer Uccelli
Journal:  Drugs       Date:  2010-07-09       Impact factor: 9.546

Review 8.  Management of pain in multiple sclerosis: a pharmacological approach.

Authors:  Claudio Solaro; Michele Messmer Uccelli
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

Review 9.  Multiple sclerosis: basic knowledge and new insights in perioperative management.

Authors:  Alexandros Makris; Alexandros Piperopoulos; Iosifina Karmaniolou
Journal:  J Anesth       Date:  2013-08-21       Impact factor: 2.078

Review 10.  Current management of pain associated with multiple sclerosis.

Authors:  Walter Pöllmann; Wolfgang Feneberg
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.